These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

349 related items for PubMed ID: 18501236

  • 1. Tumor necrosis factor antagonist responsiveness in a United States rheumatoid arthritis cohort.
    Greenberg JD, Kishimoto M, Strand V, Cohen SB, Olenginski TP, Harrington T, Kafka SP, Reed G, Kremer JM, Consortium of Rheumatology Researchers of North America Investigators.
    Am J Med; 2008 Jun; 121(6):532-8. PubMed ID: 18501236
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials.
    Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M, Wassenberg S, Kapelle A, Listing J.
    Arthritis Rheum; 2006 Nov; 54(11):3399-407. PubMed ID: 17075823
    [Abstract] [Full Text] [Related]

  • 3. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [Abstract] [Full Text] [Related]

  • 4. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry.
    Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, Dehoratius R, Kishimoto M, Kremer JM, CORRONA Investigators.
    Ann Rheum Dis; 2012 Jul; 71(7):1134-42. PubMed ID: 22294625
    [Abstract] [Full Text] [Related]

  • 5. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice.
    Kievit W, Fransen J, Oerlemans AJ, Kuper HH, van der Laar MA, de Rooij DJ, De Gendt CM, Ronday KH, Jansen TL, van Oijen PC, Brus HL, Adang EM, van Riel PL.
    Ann Rheum Dis; 2007 Nov; 66(11):1473-8. PubMed ID: 17426065
    [Abstract] [Full Text] [Related]

  • 6. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA, Klingman D, Hazard E, Ray S.
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [Abstract] [Full Text] [Related]

  • 7. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis.
    Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R.
    Pharmacotherapy; 2010 Apr; 30(4):339-53. PubMed ID: 20334454
    [Abstract] [Full Text] [Related]

  • 8. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N, den Broeder AA, Jacobs W, van der Maas A, Bijlsma JW, van Vollenhoven RF, van den Bemt BJ.
    Cochrane Database Syst Rev; 2014 Sep 29; (9):CD010455. PubMed ID: 25264908
    [Abstract] [Full Text] [Related]

  • 9. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
    Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Østergaard M, All Departments of Rheumatology in Denmark.
    Arthritis Rheum; 2010 Jan 29; 62(1):22-32. PubMed ID: 20039405
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.
    Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, Oezer U, Kary S, Kupper H, Burmester GR, Research in Active Rheumatoid Arthritis (ReAct) Study Group.
    Rheumatology (Oxford); 2007 Jul 29; 46(7):1191-9. PubMed ID: 17504821
    [Abstract] [Full Text] [Related]

  • 11. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review.
    Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsøe B, Saxne T.
    Scand J Rheumatol; 2007 Jul 29; 36(6):411-7. PubMed ID: 18092260
    [Abstract] [Full Text] [Related]

  • 12. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons.
    Nixon R, Bansback N, Brennan A.
    Rheumatology (Oxford); 2007 Jul 29; 46(7):1140-7. PubMed ID: 17478472
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis.
    Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH.
    Ann Rheum Dis; 2003 Nov 29; 62 Suppl 2(Suppl 2):ii13-6. PubMed ID: 14532140
    [Abstract] [Full Text] [Related]

  • 14. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
    Saougou I, Markatseli TE, Papagoras C, Voulgari PV, Alamanos Y, Drosos AA.
    Semin Arthritis Rheum; 2011 Apr 29; 40(5):398-406. PubMed ID: 20843542
    [Abstract] [Full Text] [Related]

  • 15. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU, GO-AFTER study investigators.
    Lancet; 2009 Jul 18; 374(9685):210-21. PubMed ID: 19560810
    [Abstract] [Full Text] [Related]

  • 16. [Rituximab in patients with rheumatoid arthritis: systematic review].
    Brodszky V, Czirják L, Géher P, Hodinka L, Kárpáti K, Péntek M, Poór G, Szekanecz Z, Gulácsi L.
    Orv Hetil; 2007 Oct 07; 148(40):1883-93. PubMed ID: 17905683
    [Abstract] [Full Text] [Related]

  • 17. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW.
    J Rheumatol; 2011 Jul 07; 38(7):1273-81. PubMed ID: 21572150
    [Abstract] [Full Text] [Related]

  • 18. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
    Markatseli TE, Alamanos Y, Saougou I, Voulgari PV, Drosos AA.
    Clin Exp Rheumatol; 2012 Jul 07; 30(1):31-8. PubMed ID: 22153557
    [Abstract] [Full Text] [Related]

  • 19. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A.
    JAMA; 2009 Feb 18; 301(7):737-44. PubMed ID: 19224750
    [Abstract] [Full Text] [Related]

  • 20. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
    Collamer AN, Battafarano DF.
    Semin Arthritis Rheum; 2010 Dec 18; 40(3):233-40. PubMed ID: 20580412
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.